Capricor Therapeutics fell 13% on Friday to $26.44, erasing the twin weekly gains that had animated two consecutive "bears losing ground" narratives — and the short position that rebuilt so aggressively last week shows no sign of retreating.
The positioning story has a now-familiar shape, but this week the price action validates the bear thesis in a way the previous two notes could not. Short interest is at 28.0% of the free float — 12.8 million shares, up 10.7% on the week and 14.6% over the past month. That is the highest level in the 30-day history, confirming what the June 26 note flagged: the June 18 covering was a pause, not a pivot. The ORTEX short score is 77.96, fractionally off its 79.0 peak from June 24 but still running near a multi-week high. Days to cover per FINRA data are 13.7, meaning unwinding this position at current volumes takes two-and-a-half weeks. For context, the score was 74.8 on June 12 — it has climbed in an almost unbroken line since.
The borrow market continues to tell a contradictory story. Despite 28% of the float being short, cost to borrow is just 0.65% — rock-bottom for a clinical-stage small-cap biotech carrying this much bear activity. Availability is 169%, meaning there are roughly 1.7 shares available to lend for every share already borrowed. That is tighter than mid-May levels, when availability was running above 330%, but far from the stress zone: the 52-week low on availability was 0.07%, a level that would signal genuine borrow scarcity. The current setup means new shorts can still enter cheaply and easily. There is no squeeze pressure in the lending market.
Options positioning reinforces the bullish lean among active traders, which makes the short interest divergence starker. The put/call ratio is 0.33, nearly 1.7 standard deviations below its 20-day average of 0.38 — call buyers are dominating the options market even as short sellers pile in on the equity side. The PCR has compressed steadily since mid-May, when it sat above 0.45. That is an unusually wide split: heavy directional bets against the stock in the equity lending market, and heavy directional bets for the stock in options. One side is wrong, and Thursday's 13% drop suggests the equity market is currently scoring the point.
On the ownership side, the institutional picture has two notable currents running against each other. Suvretta Capital added nearly 2.9 million shares in Q1, Tang Capital added 1.7 million, and State Street added 1.35 million — all meaningful builds. Point72, by contrast, trimmed 1 million shares in the same period, one of the larger single-manager reductions in the holder list. Insider activity is a softer signal this week: the CFO and General Counsel both sold small lots at $30 on June 22 and June 24 — well above Friday's close — trades that appear routine in size but carry a timing note given where the stock has since moved. The May 1 paired sale of 25,000 shares each by the same two insiders at $31.70 follows the same pattern, all sales, no purchases in the 90-day record.
With Q1 earnings already in the books — the stock fell roughly 5% the day after the May 12 print and 15.6% over the following five days — the next scheduled event is the August 6 Q2 report. That gives the tug-of-war between a record-high short position and call-heavy options positioning roughly six weeks to play out before the next hard catalyst, with Friday's sharp sell-off the clearest signal yet of which camp has held the initiative this week.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
